3 Million+ Unique Research Compounds, Real-time Pricing & Availability
Sign in to enjoy up to 20% OFF or Sign Up
  • Product Search
     
[email protected]
  • Product Search
     
Chemistry
Bioactive Molecules
Screening Libraries
Natural Products
Material Science
ADCs
PEG
Biologics
Consumables
+1 800-931-7508 [email protected]
Sign in to enjoy up to 20% OFF

[CAS NO. 1446321-46-5]  Voxelotor

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1446321-46-5]

Distributor
Catalog
AS941371
Brand
Arctom Scientific
CAS
1446321-46-5

DESCRIPTION [1446321-46-5]

Overview

MDLMFCD29053764
Molecular Weight337.37
Molecular FormulaC19H19N3O3
SMILESOC1=CC=CC(OCC2=C(C3=CC=NN3C(C)C)N=CC=C2)=C1C=O

For research use only. We do not sell to patients.

6 Publications Citing Use of MCE


Summary

Voxelotor (GBT 440) is a potent inhibitor of haemoglobin S (HbS) polymerization . Voxelotor has the potential for sickle cell disease (SCD) treatment [1] .


IC50 & Target

HbS polymerization [1]


In Vitro

Voxelotor (GBT440) binds to the N-terminal a chain of haemoglobin (Hb), increases haemoglobin S (HbS) affinity for oxygen, delays in vitro HbS polymerization and prevents sickling of red blood cells (RBCs) [1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.


In Vivo

Voxelotor (GBT440; 100-150 mg/kg; administered twice a day by oral gavage for 9-12 days) reduces ex vivo sickling and prolongs red blood cells (RBCs) half-life in a murine model of sickle cell disease (SCD) [1] .
Voxelotor shows T 1/2 s of 11.7, 19.1±1.5, 66.0±11, 28.8±4.0 hours for mouse (70 mg/kg; i.v.), rat (1.6 mg/kg; i.v.), dog (1 mg/kg; i.v.), and momkey (1 mg/kg; i.v.), respectively [1] .
Voxelotor shows C max s of 81.9, 71.2±6.0, 5.56±1.6, and 25.2±5.5 μg/mL for mouse (30 mg/kg; p.o.), rat (7.2 mg/kg; p.o.), dog (2.5 mg/kg; p.o.), and momkey (4.25 mg/kg; p.o.), respectively [1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: HbSS Townes knock-in sickle mice (SS mice) [1]
Dosage: 100 and 150 mg/kg
Administration: Oral administration; twice a day; for 9-12 days
Result: Reduced haemolysis.
Animal Model: C57BL/6J mice, Sprague-Dawley rats, Beagle dogs and Cynomolgus monkeys [1]
Dosage: 70, 1.6, 1 and 1 mg/kg for mice, rats, dogs and monkeys, respectively
30, 7.2, 2.5 and 4.25 mg/kg for mice, rats, dogs and monkeys, respectively
Administration: Intravenous (IV: 70, 1 6, 1 and 1 mg/kg, respectively)
Oral (PO: 30, 7 2, 2 5 and 4 3 mg/kg, respectively)
Result: T 1/2 s of 11.7, 19.1±1.5, 66.0±11, 28.8±4.0 hours for mouse (70 mg/kg; i.v.), rat (1.6 mg/kg; i.v.), dog (1 mg/kg; i.v.), and momkey (1 mg/kg; i.v.), respectively.
C max s of 81.9, 71.2±6.0, 5.56±1.6, and 25.2±5.5 μg/mL for mouse (30 mg/kg; p.o.), rat (7.2 mg/kg; p.o.), dog (2.5 mg/kg; p.o.), and momkey (4.25 mg/kg; p.o.), respectively.

Clinical Trial

NCT Number Sponsor Condition Start Date Phase
NCT04724421 Global Blood Therapeutics
Sickle Cell Disease
NCT03114540 Global Blood Therapeutics
Hepatic Impairment
March 17, 2017 Phase 1
NCT02567682 Global Blood Therapeutics
Sickle Cell Disease
September 2015 Phase 1

Appearance

Solid


Shipping

Room temperature in continental US; may vary elsewhere.


Storage

4°C, stored under nitrogen

* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)


Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL ( 296.41 mM ; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.9641 mL 14.8205 mL 29.6410 mL
5 mM 0.5928 mL 2.9641 mL 5.9282 mL
10 mM 0.2964 mL 1.4821 mL 2.9641 mL
* Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one: 5% DMSO >> 40% PEG300 >> 5% Tween-80 >> 50% saline

    Solubility: ≥ 2.5 mg/mL (7.41 mM); Clear solution

  • 2.

    Add each solvent one by one: 5% DMSO >> 95% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (7.41 mM); Clear solution

  • 3.

    Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

    Solubility: ≥ 2.08 mg/mL (6.17 mM); Clear solution

  • 4.

    Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.08 mg/mL (6.17 mM); Clear solution

  • 5.

    Add each solvent one by one: 10% DMSO >> 90% corn oil

    Solubility: ≥ 2.08 mg/mL (6.17 mM); Clear solution

  • 6.

    Add each solvent one by one: 1% DMSO >> 99% saline

    Solubility: 0.5 mg/mL (1.48 mM); Suspended solution; Need ultrasonic

* All of the co-solvents are available by MCE.


Synonyms

Benzaldehyde, 2-hydroxy-6-[[2-[1-(1-methylethyl)-1H-pyrazol-5-yl]-3-pyridinyl]methoxy]-
2-Hydroxy-6-[[2-[1-(1-methylethyl)-1H-pyrazol-5-yl]-3-pyridinyl]methoxy]benzaldehyde
GBT 440
Voxelotor
2-hydroxy-6-{[2-[1-(propan-2-yl)-1H-pyrazol-5-yl]pyridin-3-yl]methoxy}benzaldehyde
Oxbryta
2-Hydroxy-6-([2-[1-(propan-2-yl)-1H-pyrazol-5-yl]pyridin-3-yl]methoxy)benzaldehyde
2-Hydroxy-6-[[2-(2-propan-2-ylpyrazol-3-yl)pyridin-3-yl]methoxy]benzaldehyde

Information
Shipping
Privacy Notice
Terms of Service
About Us
Contact Us
FAQs
Customer service
Search
Custom Synthesis
My account
My account
Orders
Addresses
Shopping Cart
Suppliers
Supplier Sign In
Become a Supplier
Pay
Follow us
Powered by Arctom Copyright © 2026 Arctom. All rights reserved.